Clinical trials: Helicobacter
Helicobacter Pylori Infection
Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants
This is a single-center, randomized, open-label phase Ic/IIb clinical study to evaluate the efficacy and safety of TNP-2198 capsules, rabeprazole sodium enteric-coated tablets and amoxicillin capsules combined with multiple doses…
- Trial name
- NCT06076694
- Testing
- TNP-2198, Rabeprazole Sodium, Amoxicillin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- TenNor Therapeutics (Suzhou) Limited
Helicobacter Pylori Infection
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days
The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy.
- Trial name
- NCT04901117
- Testing
- Amoxicillin, Clarithromycin, Tetracycline
- Where
- China
- Volunteers
- 1,300 people
- Sponsor
- Shandong University
Helicobacter Pylori Infection
A Phase 1 Study to Evaluate PK Profile of Multiple Oral Administrations of TNP-2092 Capsules in Healthy Subjects
This study was a single-center, randomized, double-blind, placebo-controlled, dose-ascending multiple-dose-administration study.
- Trial name
- NCT06190340
- Testing
- TNP-2092 capsules
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- TenNor Therapeutics (Suzhou) Limited
Helicobacter Pylori Infection
Optimization of Vonoprazan-based Dual Therapy for Helicobacter Pylori
The purpose of this study was to evaluate the efficacy and safety of vonoprazan with different doses of amoxicillin for Helicobacter Pylori.
- Trial name
- NCT05649540
- Testing
- Vonoprazan, Amoxicillin
- Where
- 13 sites in China
- Volunteers
- 900 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Helicobacter Pylori Infection
Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori
This randomized controlled study aimed to evaluate whether adding bismuth to the standard first-line triple therapy could improve the eradication rate of Helicobacter pylori (H. pylori). A total of 162 patients with H.
- Trial name
- NCT03108287
- Testing
- RAK therapy, RBAK therapy
- Volunteers
- 162 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
H Pylori Infection, Atherogenic Plasma Index
H. Pylori Infection and AIP Levels
Helicobacter pylori is a common bacterial infection of the stomach that can cause ulcers and other digestive problems. Recent studies suggest that this infection may also affect metabolism and blood fats (lipids), which are…
- Trial name
- HP-AIP (NCT07306377)
- Testing
- urea breath test
- Where
- Egypt
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Tanta University
Helicobacter-associated Gastritis
Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori
Current Helicobacter Pylori infection preferred treatment involves; proton pump inhibitor (PPI)-based triple or qudrable regimens.
- Trial name
- NCT02422706
- Testing
- Nitazoxanide, Metronidazole(MTZ), Omeprazole
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Sherief Abd-Elsalam
Helicobacter Pylori Infection, Intravenous Drug Usage
Intravenous Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease
Helicobacter pylori infection causes active peptic ulcer disease and related complications like bleeding and pyloric obstruction.
- Trial name
- NCT04432233
- Testing
- Esomeprazole, Metronidazole, Levofloxacin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Helicobacter Pylori Infection
Arrangement of Collecting Venules for the Endoscopic Diagnosis of Helicobacter Pylori
To perform a prospective, observational, international, multicentre, in vivo study to assess the performance of regular arrangement of collecting venules (RAC) for the exclusion of Helicobacter pylori (Hp) infection using white…
- Trial name
- MOTIVATION (NCT05046990)
- Testing
- Regular Arrangement of Collecting Venules
- Where
- 5 sites in Belgium, Germany and 1 more
- Volunteers
- 1,000 people
- Sponsor
- Hospital Clinic of Barcelona
Probiotic, Gut Microbiota
The Effects of Yogurt on Gut Microbiome and Metabolism in H. Pylori.
Helicobacter pylori is a common pathogen causing upper gastrointestinal diseases including gastric ulcer and gastric cancer. Recent epidemiological findings have also shown that it is also related to colon cancer, metabolic…
- Conditions
- Probiotic, Gut Microbiota, Helicobacter Pylori Infection, Insulin Resistance
- Trial name
- NCT05374980
- Testing
- Yogurt
- Where
- Taiwan
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Taichung Veterans General Hospital
Helicobacter Pylori Infection
Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies
Both hybrid and high-dose dual therapies developed by the scholars from Taiwan can achieve a high eradication rate for clarithromycin-resistant strains, and have a great potential to replace bismuth quadruple therapy in the…
- Trial name
- NCT03779074
- Testing
- 10d bismuth quadruple therapy, 14d hybrid therapy, 14D high-dose dual therapy
- Where
- Taiwan
- Volunteers
- 918 people
- Sponsor
- Kaohsiung Veterans General Hospital.
HELICOBACTER PYLORI INFECTIONS, Rescue Therapy for Helicobacter Pylori
Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing
Helicobacter pylori(H. pylori, Hp) is a major etiological agent in chronic gastritis, peptic ulcer disease, gastric cancer, and gastric MALT lymphoma.
- Trial name
- NCT07533422
- Testing
- Personalized treatment based on the results of fecal antimicrobial resistance gene testing, Conventional Quadruple Therapy
- Volunteers
- 531 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Helicobacter Pylori
Association of Oral Helicobacter Pylori Infection With Gastric Helicobacter Pylori Infection
The aim of this study was to investigate the association between oral Helicobacter pylori infection and gastric Helicobacter pylori infection.
- Trial name
- NCT05790512
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital of Digestive Diseases
HELICOBACTER PYLORI INFECTIONS
Efficacy and Safety of 7-day Triple Therapy Containing Amoxicillin and Tetracycline Versus 14-day Dual Therapy for Helicobacter Pylori Eradication
With the increasing prevalence of antibiotic resistance, the clinical efficacy of conventional 7-day triple therapy for Helicobacter pylori eradication has been substantially diminished.
- Trial name
- PSM (NCT07333001)
- Testing
- 7-day triple therapy, 14-day dual therapy
- Where
- China
- Volunteers
- 508 people
- Sponsor
- Yueyue Li
Gastritis
The Metabolic Contribution of the Human Microbiota to Resting Energy Expenditure
The purpose of our study is to evaluate the metabolic contribution of the human microbiota to resting energy expenditure
- Trial name
- A-P-REE (NCT00487955)
- Testing
- Resting Energy Expenditure examination
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Helicobacter Infection
The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori
As increasing the antibiotics resistance, the effectiveness of traditional Helicobacter pylori (H. pylori) therapies has been declined coincidently. In this study, the investigators evaluated the efficacy of H.
- Trial name
- NCT02349685
- Testing
- H. pylori culture and antimicrobial susceptibility test, 14 day PBMT group, 14 day MEA group
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Seoul National University Bundang Hospital
Helicobacter Pylori
The Study of the Antimicrobial Resistance of Helicobacter Pylori in Shandong Province
The antimicrobial resistance of helicobacter pylori in Shandong province was analyzed by helicobacter pylori antibiotic sensitivity test.And the map of antimicrobial resistance of helicobacter pylori was constructed to provide…
- Trial name
- NCT04029415
- Where
- China
- Volunteers
- 1,800 people
- Sponsor
- Shandong University
Helicobacter Pylori Infection, Antibiotic Resistant Infection
Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.
The aim of our study will be to assess in an open-label, multicenter, randomized controlled trial whether a tailored therapy guided by a non-invasive antibiotic susceptibility test on stool samples achieves higher Helicobacter…
- Conditions
- Helicobacter Pylori Infection, Antibiotic Resistant Infection, Antibiotic Resistant Strain
- Trial name
- THD-HP (NCT04107194)
- Testing
- Pantoprazole 40mg, Amoxicillin 1000 MG, Clarithromycin 500mg
- Where
- Italy
- Volunteers
- 362 people
- Sponsor
- University of Bari
Helicobacter Pylori Infection, Helicobacter Pylori Eradication Antibiotic
The Impact of Helicobacter Pylori Eradication on the Vaginal Microecology Change
This clinical controlled study enrolled 73 H. pylori（Helicobacter Pylori ）-infected female participants, stratified into reproductive-age and menopausal cohorts, alongside 10 non-infected controls.
- Trial name
- NCT07408271
- Testing
- rabeprazole-based triple therapy plus bismuth H. pylori eradication therapy
- Where
- China
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Parkinson's Disease, Helicobacter Infections
Treating H. Pylori in Parkinson's Patients With Motor Fluctuations
The purpose of this study is to determine whether treatment of H. pylori (an infection of the stomach) improves treatment effectiveness in patients with Parkinson's disease and motor fluctuations.
- Conditions
- Parkinson's Disease, Helicobacter Infections, Motor Fluctuations
- Trial name
- NCT00664209
- Testing
- clartihromycin, amoxicillin, and omeprazole
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of California, Los Angeles